This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yanase, T. Articles by Tanaka, K. Search for Related Content PubMed PubMed Citation Articles by Yanase, T. Articles by Tanaka, K.

Inhibitory Effect of Angiogenesis Inhibitor TNP-470 on Tumor Growth and Metastasis of Human Cell Lines in Vitro and in Vivo

Department of Obstetrics and Gynecology, Niigata University School of Medicine, 1, Asahimachi-dori, Niigata 951, Japan

Antitumor activity of angiogenesis inhibitor TNP-470 was evaluated in eight human cultured cell lines derived from choriocarcinoma: SCH, NUC-1, and GCH-1(m); ovarian cancer; TYK and Nakajima; and uterine endometrial cancer: HEC-6, HEC-50, and HEC-1-A. After 7-day culture with TNP-470, in medium at the concentration of 10¹ to 10^-2 µg/ml, the inhibition of growth was observed in all of the eight cell lines. The 50% inhibitory concentration of choriocarcinoma cell lines was at an extremely low level compared to that of epithelial ovarian cancer and uterine endometrial cancer. In addition, the antitumor effect of this compound was studied in in vivo experiments using nude mice with tumors of GCH-1(m), NUC-1, or Nakajima cells. When the size of the transplanted tumor reached 100–200 mm³ in volume, 3, 10, or 30 mg/kg of TNP-470 was injected s.c. every other day. The inhibitory effect of TNP-470 was obtained by the administration of 10 and 30 mg/kg in GCH-1(m) and NUC-1 cells, respectively, while in Nakajima cells no significant effect was observed. In nude mice treated with 30 mg/kg of TNP-470, lung metastasis of GCH-1(m) cells was strongly inhibited both in the number and in the size of tumor nodules, indicating that the capillary growth in the originally developed tumor was also significantly reduced. These results suggest that the clinical setting using TNP-470 may be one of the promising treatments for the metastasis of tumor cells.

¹ To whom requests for reprints should be addressed.

Received 12/15/92. Accepted 4/20/93.

This article has been cited by other articles:

				P. J. Didier, J. N. Phillips, D. J. Kuebler, M. Nasr, P. J. Brindley, M. E. Stovall, L. C. Bowers, and E. S. Didier Antimicrosporidial Activities of Fumagillin, TNP-470, Ovalicin, and Ovalicin Derivatives In Vitro and In Vivo. Antimicrob. Agents Chemother., June 1, 2006; 50(6): 2146 - 2155. [Abstract] [Full Text] [PDF]

				M. Yamaguchi, F. Matsumoto, H. Bujo, M. Shibasaki, K. Takahashi, S. Yoshimoto, M. Ichinose, and Y. Saito Revascularization Determines Volume Retention and Gene Expression by Fat Grafts in Mice Experimental Biology and Medicine, November 1, 2005; 230(10): 742 - 748. [Abstract] [Full Text] [PDF]

				M. Muramaki, H. Miyake, I. Hara, and S. Kamidono Introduction of Midkine Gene into Human Bladder Cancer Cells Enhances Their Malignant Phenotype But Increases Their Sensitivity to Antiangiogenic Therapy Clin. Cancer Res., November 1, 2003; 9(14): 5152 - 5160. [Abstract] [Full Text] [PDF]

				T. Su, M. Suzui, L. Wang, C.-S. Lin, W.-Q. Xing, and I. B. Weinstein Deletion of histidine triad nucleotide-binding protein 1/PKC-interacting protein in mice enhances cell growth and carcinogenesis PNAS, June 24, 2003; 100(13): 7824 - 7829. [Abstract] [Full Text] [PDF]

				S. Koyanagi, H. Nakagawa, Y. Kuramoto, S. Ohdo, S. Soeda, and H. Shimeno Optimizing the Dosing Schedule of TNP-470 [O-(Chloroacetyl-carbamoyl) Fumagillol] Enhances Its Antitumor and Antiangiogenic Efficacies J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 669 - 674. [Abstract] [Full Text] [PDF]

				K. Inoue, M. Chikazawa, S. Fukata, C. Yoshikawa, and T. Shuin Docetaxel Enhances the Therapeutic Effect of the Angiogenesis Inhibitor TNP-470 (AGM-1470) in Metastatic Human Transitional Cell Carcinoma Clin. Cancer Res., February 1, 2003; 9(2): 886 - 899. [Abstract] [Full Text] [PDF]

				H. Endo, K. Takenaga, T. Kanno, H. Satoh, and S. Mori Methionine Aminopeptidase 2 Is a New Target for the Metastasis-associated Protein, S100A4 J. Biol. Chem., July 12, 2002; 277(29): 26396 - 26402. [Abstract] [Full Text] [PDF]

				K. Inoue, M. Chikazawa, S. Fukata, C. Yoshikawa, and T. Shuin Frequent Administration of Angiogenesis Inhibitor TNP-470 (AGM-1470) at an Optimal Biological Dose Inhibits Tumor Growth and Metastasis of Metastatic Human Transitional Cell Carcinoma in the Urinary Bladder Clin. Cancer Res., July 1, 2002; 8(7): 2389 - 2398. [Abstract] [Full Text] [PDF]

				A. Catalano, M. Romano, I. Robuffo, L. Strizzi, and A. Procopio Methionine Aminopeptidase-2 Regulates Human Mesothelioma Cell Survival : Role of Bcl-2 Expression and Telomerase Activity Am. J. Pathol., August 1, 2001; 159(2): 721 - 731. [Abstract] [Full Text]

				P. J. Mahasreshti, J. G. Navarro, M. Kataram, M. H. Wang, D. Carey, G. P. Siegal, M. N. Barnes, D. M. Nettelbeck, R. D. Alvarez, A. Hemminki, et al. Adenovirus-mediated Soluble FLT-1 Gene Therapy for Ovarian Carcinoma Clin. Cancer Res., July 1, 2001; 7(7): 2057 - 2066. [Abstract] [Full Text] [PDF]

				S. Shusterman, S. A. Grupp, R. Barr, D. Carpentieri, H. Zhao, and J. M. Maris The Angiogenesis Inhibitor TNP-470 Effectively Inhibits Human Neuroblastoma Xenograft Growth, Especially in the Setting of Subclinical Disease Clin. Cancer Res., April 1, 2001; 7(4): 977 - 984. [Abstract] [Full Text]

				J. W. Stern, J. Fang, S. Shusterman, G. Pierson, R. Barr, B. Pawel, L. Diller, and S. A. Grupp Angiogenesis Inhibitor TNP-470 during Bone Marrow Transplant: Safety in a Preclinical Model Clin. Cancer Res., April 1, 2001; 7(4): 1026 - 1032. [Abstract] [Full Text]

				Y. Zhang, E. C. Griffith, J. Sage, T. Jacks, and J. O. Liu Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1 PNAS, June 6, 2000; 97(12): 6427 - 6432. [Abstract] [Full Text] [PDF]

				W. M. Stadler, T. Kuzel, C. Shapiro, J. Sosman, J. Clark, and N. J. Vogelzang Multi-Institutional Study of the Angiogenesis Inhibitor TNP-470 in Metastatic Renal Carcinoma J. Clin. Oncol., August 1, 1999; 17(8): 2541 - 2541. [Abstract] [Full Text] [PDF]

				P. Bhargava, J. L. Marshall, N. Rizvi, W. Dahut, J. Yoe, M. Figuera, K. Phipps, V. S. Ong, A. Kato, and M. J. Hawkins A Phase I and Pharmacokinetic Study of TNP-470 Administered Weekly to Patients with Advanced Cancer Clin. Cancer Res., August 1, 1999; 5(8): 1989 - 1995. [Abstract] [Full Text] [PDF]

				A. P. Kudelka, C. F. Verschraegen, and E. Loyer Complete Remission of Metastatic Cervical Cancer with the Angiogenesis Inhibitor TNP-470 N. Engl. J. Med., April 2, 1998; 338(14): 991 - 992. [Full Text]

				H. Koyama, Y. Nishizawa, M. Hosoi, S. Fukumoto, K. Kogawa, A. Shioi, and H. Morii The Fumagillin Analogue TNP-470 Inhibits DNA Synthesis of Vascular Smooth Muscle Cells Stimulated by Platelet-Derived Growth Factor and Insulin-like Growth Factor-I: Possible Involvement of Cyclin-Dependent Kinase 2 Circ. Res., October 1, 1996; 79(4): 757 - 764. [Abstract] [Full Text]

				K. R. Dover and A. W. Valley Review : Angiogenesis: A new target for antineoplastic therapy Journal of Oncology Pharmacy Practice, January 1, 1996; 2(1): 43 - 60. [Abstract] [PDF]